Rocket Lab USA (NASDAQ: RKLB) has staged a notable recovery after a brutal summer sell-off that erased more than half its value. The small-launch and space-systems company peaked near $151 in May before the SpaceX IPO triggered a sector-wide rotation that hammered space equities. With second-quarter earnings now digested and a steady drumbeat of defense-contract wins, the stock has found firm footing around the $60 level—a price zone that has acted as multi-year support.
Earnings Remove a Key Overhang
The August 10 quarterly report delivered record revenue and pushed total backlog past $2.3 billion, alongside more than $1 billion in new bookings during the period. While Q3 margin guidance softened on heavy Neutron development spending, the print confirmed operational momentum. Investors can now shift focus from past results to the catalysts ahead, primarily the maiden flight of the medium-lift Neutron rocket slated for the fourth quarter.
Defense Pipeline Deepens
Contract momentum has not paused during the share-price decline. In recent weeks Rocket Lab joined the U.S. Space Force’s NITE-STAR wargaming architecture (ceiling up to $981 million across participants), secured a geostationary satellite-bus role from Viasat for a protected military communications system, and won a separate award tied to the Space Force’s Space Data Network. These follow the $397 million Flatellite constellation award and a record $266 million missile-defense launch deal announced earlier in August. The pattern underscores a transformation into a bona-fide national-security contractor with a compounding defense backlog.
Why the Rally Has Been Cautious
Despite the contract flow, the stock has struggled to sustain gains on news. Two factors dominate: valuation and Neutron execution risk. Even after the drawdown, Rocket Lab trades above 70 times trailing sales—an extraordinary multiple for a company still posting a trailing net loss near $198 million. The market is demanding proof of profitability and Neutron’s commercial viability before re-rating the shares. A Stage 1 tank issue pushed Neutron’s debut to Q4, keeping a portion of the bull case theoretical.
Technical and Analyst Backdrop
The $60 area has been tested repeatedly across several years and held again in late July, offering a well-defined risk level for longs. Meanwhile, the analyst community remains constructive: 22 covering analysts rate the stock a consensus Moderate Buy with a $110.65 average price target, implying roughly 50% upside. Only one analyst carries a Sell rating.
Bottom Line
“Safe” is a relative term for a stock with a 2.6 beta that can swing double digits in a week. Yet for investors with a multi-quarter horizon, the setup is arguably the most attractive since spring. Selling pressure from the SpaceX rotation is fading, fundamentals are at historic highs, and the defense pipeline is deepening weekly. The real re-rating catalyst remains Neutron’s first launch—until then, volatility is the price of admission.
Frequently Asked Questions
- What is Rocket Lab’s Neutron rocket and why does it matter? Neutron is a reusable, medium-lift launch vehicle designed to carry up to 13 metric tons to low Earth orbit. It dramatically expands Rocket Lab’s addressable market beyond the small-sat niche served by Electron and is the designated launcher for the Flatellite constellation and other defense payloads.
- Why did Rocket Lab shares fall more than 50% after the SpaceX IPO? The SpaceX listing triggered a broad rotation out of speculative space names as investors repositioned toward the newly public, dominant launch provider. Rocket Lab’s high valuation and pre-profit status made it vulnerable to risk-off flows.
- Is Rocket Lab profitable? Not yet. The company reported a trailing net loss of approximately $198 million. Management is investing heavily in Neutron development and vertical integration, which suppresses near-term margins but aims to drive long-term free-cash-flow inflection once Neutron reaches cadence.
